Gentari to supply large-scale, carbon-free energy to AMG Ammonia
650 MW firm dispatchable RE supply to power AMG Ammonia's upcoming green…
Orca Bio Presents Clinical Results on Use of Orca-Q without GvHD Prophylaxis in Patients with Hematological Malignancies at the 66th ASH Annual Meeting
Orca-Q allogeneic T-cell immunotherapy with no GvHD prophylaxis in patients with matched…
Twenty-three Years Running for the Kids of St. Jude: St. Jude Memphis Marathon Weekend Reaches Fundraising Record
MEMPHIS, Tenn.--(BUSINESS WIRE)--The 2024 St. Jude Memphis Marathon Weekend®, presented by Juice…
Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for -Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels
Treatment effects sustained through long-term follow-up of beyond 10 years in the…
MiNA Therapeutics Presents New Pre-Clinical Data from Lead Sickle Cell Disease Program at the American Society of Hematology Annual Meeting
MTL-HBG drug candidate demonstrated best-in-class activity and safety in pre-clinical models Data…
City of Hope Scientists Present Innovative Research on How High-Fiber Diets Can Improve Outcomes in Cancer Care
Studies related to microbiome were presented today at the American Society of…
TEDA Celebrates 40 Years of Pioneering Innovation, Inclusive Opening-up, and Synergistic development
TIANJIN, China, Dec. 7, 2024 /PRNewswire/ -- The Tianjin Economic-Technological Development Area ("TEDA"), established…
Embitel continues its journey with the Volkswagen Group, advancing toward a brighter digital future
BENGALURU, India, Dec. 7, 2024 /PRNewswire/ -- Embitel Technologies, a globally recognized provider…
University of Phoenix College of Doctoral Studies Celebrates a Robust 2024 Knowledge Without Boundaries Summit With Record 1,000+ Attendees
Annual event fosters diverse perspectives, recognizes accomplishments, and helps prepare students for…
Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer
— Phase 3 POD1UM-304 trial met primary endpoint of overall survival (OS)…
